It's also odd not to release any of the 'quantitative' data with the announcement. Saying the drug did not meet end-points without some sort of explanation is bizarre. The PI would know exactly what the 'data' read out is.
James also said we have multiple grabs of the cherry here, more read outs in 2025 as boys remain on after the initial 6 months.
To stop all trial activity now right now - makes me think something not quite right with trial design, clinical cred, drug manufacture...something smells here.
I guess that's why Moses is getting involved.
.
PER Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)